Don't Wait for Fed to Cut Rates. Profit Now!

12:00pm, Saturday, 04'th May 2024
Investors wait for the Fed starting gun
Eli Lilly's Mounjaro is a diabetes medication that competes with Novo Nordisk's Ozempic. Lilly is making strides in the weight-loss market, and its newest treatment may be a smashing success.
The outlook for Pfizer's experimental obesity drug danuglipron is murky at best. Pfizer could pick up another obesity drug via an acquisition, but management says a near-term deal is unlikely.
Eli Lilly stock is way up over the past year, but analysts who follow the company think it still has more upside. Sales of Eli Lilly's weight-management treatment are soaring and could climb much high
The pharmaceutical sector mainstay has attracted much attention with a recently approved drug. It also posted impressive quarterly results at the end of April.

Earnings Season: 3 Companies Boosting Guidance

04:01pm, Thursday, 02'nd May 2024
Earnings season continues to chug along, with results from many companies already delivered. And concerning positivity, all three of these companies' report fit the criteria, lifting outlooks followin
Lilly's Mounjaro and Zepbound should have tremendous growth ahead. The company could have even better weight loss drugs in its pipeline.
Many have come to believe that artificial intelligence is the next stepping stone to propel the global economy to new heights. However, the giant on whose shoulder stands the development of AI is the
Identifying the next trillion-dollar market is a serious challenge. Reaching a trillion-dollar market cap symbolizes more than just financial success; it reflects a company's profound global impact, e
We're a little more than halfway through first-quarter earnings season, so now is the time to review this earnings season winners and losers. In general, market results have been encouraging so far.

Trade Tracker: Joe Terranova sells Eli Lilly

01:49pm, Wednesday, 01'st May 2024
The Investment Committee discusses the healthcare sector as Joe Terranova sells Eli Lilly in his JOET rebalance.
Eli Lilly and Company (LLY) raised its outlook for 2024 on rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro.
While a weakening economy and a subsequent dip in the stock market are unfortunate, they are inevitabilities. Even booming segments like the biotech sector are not immune to the general trend of reces
Stanley Druckenmiller has one of the best investing records out there. He worked closely with George Soros, helping to "break the Bank of England.

These 3 Companies Recently Lifted Guidance

06:56pm, Tuesday, 30'th Apr 2024
Guidance lifts are among the most positive announcements shareholders can hear, injecting confidence in the long-term picture.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE